Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate-amodiaquine versus artemether-lumefantrine in pregnant women with uncomplicated malaria in Tanzania
PACTR202610806872823Phase 4Not yet recruiting
- Sponsor
- Muhimbili University of Health and Allied Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of artesunate, amodiaquine, artemether and lumefantrine in Malaria (2 arms), sponsored by Muhimbili University of Health and Allied Sciences. Primary endpoint: PCR-adjusted Adequate Clinical and Parasitological Response (ACPR). Planned start Nov 2026; status: not yet recruiting.
02
Drugs
artesunateamodiaquineartemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202610806872823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610806872823.